article · NIGERIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Abstract Background and Objectives: Upper gastrointestinal bleeding (UGIB) is a major emergency. The Rockall score (RS) could be a tool to predict the outcome of patients regarding their risk of re-bleeding and/or death 30 days after admission. This study aimed to evaluate the prognostic value of the RS in patients admitted for UGIB in Yaoundé (Cameroon). Materials and Methods: We conducted a retrospective cohort study at two emergency units inYaoundé. We included 101 patients admitted from 2020 to 2021 for a UGIB and obtained the sociodemographic, clinical, and paraclinical data. The outcome 30 days after the admission was assessed (re-bleeding and/or death). We calculated the RS and analyzed the association of an RS ≥ 5 with the death of the patient and/or a re-bleeding 30 days after admission. Results: The mean age of patients was 48.5 years, 75 of the 101 were males (74.3%). The main bleeding lesions were portal hypertension in 35 patients (34.7%), gastric ulcers in 32 patients (31.7%), and duodenal ulcers in 30 patients (29.7%). During the 30 days after the admission, we recorded re-bleeding in 21 patients (20.8%) and death in 9 patients (8.9%). The RS was ≥ 5 in 49 patients (48.5%), and this was significantly associated with the re-bleeding (RR 4.5; CI 95% 1.631–12.459; P = 0.001) and with the death ( P = 0.001). Conclusion: The RS ≥ 5 is associated with a risk of re-bleeding and/or death in patients admitted for a UGIB in Yaoundé regardless of the aetiology.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4103/njgh.njgh_9_23
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.